MedTrace Logo

Systemic Erythropoietin Injection in Patients Having Optic Atrophy

NCT04680143 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-07-13

No results posted yet for this study

Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Conditions

  • Optic Atrophy

Interventions

DRUG

Systemic erythropoietin injection

Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mai ElBahwash, PhD · Alexandria Faculty of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-03-01
Completion
2021-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04680143 on ClinicalTrials.gov